AspireAssist Weight Loss Procedure Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • AspireAssist Weight Loss Procedure's estimated annual revenue is currently $1.8M per year.(i)
  • AspireAssist Weight Loss Procedure's estimated revenue per employee is $251,000

Employee Data

  • AspireAssist Weight Loss Procedure has 7 Employees.(i)
  • AspireAssist Weight Loss Procedure grew their employee count by -22% last year.

AspireAssist Weight Loss Procedure's People

NameTitleEmail/Phone
1
EVP Sales Marketing and Clinical SupportReveal Email/Phone
2
VP Regulatory & QualityReveal Email/Phone
3
Territory ManagerReveal Email/Phone
4
Supply Chain SpecialistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$73.5M29312%N/AN/A
#2
$7M28-10%N/AN/A
#3
$37.9M15113%N/AN/A
#4
$2.1M17-78%$64.3MN/A
#5
$9.3M37-10%N/AN/A
#6
$56.2M1790%N/AN/A
#7
$38.9M155-1%N/AN/A
#8
$22.1M885%N/AN/A
#9
$22.1M889%N/AN/A
#10
$33.4M13310%N/AN/A
Add Company

What Is AspireAssist Weight Loss Procedure?

Aspire Bariatrics is a medical device company that is revolutionizing the treatment of obesity with its non-surgical weight loss system, the AspireAssist. The AspireAssist was FDA approved in the United States in June 2016 based on a Randomized Clinical Trial at 10 leading institutions across the United States, including Brigham & Women's, Mayo Clinic, Northwestern University, University of Pennsylvania, Weill Cornell, and Washington University in St. Louis. The clinical study showed excellent safety and best-in-class weight loss results among endoscopic weight loss procedures. The AspireAssist is also CE-marked and commercially available the European Union, Middle East, and New Zealand. Learn more at aspirebariatrics.com

keywords:N/A

N/A

Total Funding

7

Number of Employees

$1.8M

Revenue (est)

-22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.5M70%N/A
#2
N/A70%N/A
#3
$0.4M717%N/A
#4
$1.4M9-10%N/A
#5
$0.9M10N/AN/A